These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 1882800)
1. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Terasaki S; Nakanuma Y; Ogino H; Unoura M; Kobayashi K Am J Gastroenterol; 1991 Sep; 86(9):1194-9. PubMed ID: 1882800 [TBL] [Abstract][Full Text] [Related]
2. Immunologic effects of ursodeoxycholic acid in primary biliary cirrhosis. Leevy CB; Holt J; Buniak B J Assoc Acad Minor Phys; 1993; 4(1):30-2. PubMed ID: 8425102 [TBL] [Abstract][Full Text] [Related]
4. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. Batts KP; Jorgensen RA; Dickson ER; Lindor KD Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409 [TBL] [Abstract][Full Text] [Related]
5. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382 [TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of cholestatic liver diseases with ursodeoxycholic acid]. Boberg KM; Schrumpf E Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904 [TBL] [Abstract][Full Text] [Related]
10. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990 [TBL] [Abstract][Full Text] [Related]
11. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401 [TBL] [Abstract][Full Text] [Related]
12. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Degott C; Zafrani ES; Callard P; Balkau B; Poupon RE; Poupon R Hepatology; 1999 Apr; 29(4):1007-12. PubMed ID: 10094939 [TBL] [Abstract][Full Text] [Related]
13. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377 [TBL] [Abstract][Full Text] [Related]